Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation's 12th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This manuscript, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.

• Authors: Brad S Kahl, Martin Dreyling, Leo I Gordon, Leticia Quintanilla-Martinez, Eduardo M Sotomayor
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 58 Issue 7 Pg. 1561-1569 (07 2017) ISSN: 1029-2403 [Electronic] United States
• PMID: 28140709 (Publication Type: Congress)

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cell- and Tissue-Based Therapy
• Clinical Trials as Topic
• Combined Modality Therapy
• Humans
• Immunotherapy (methods)
• Lymphoma, Mantle-Cell (diagnosis, therapy)
• Treatment Outcome